Led by Data Collective with participation from many others, including Utah-based Epic Ventures, Domo CEO Joshua James, Pluralsight CEO Aaron Skonnard, Qualtrics CEO Ryan Smith, and former Ancestry CEO Tim Sullivan.
SLC-based Recursion Pharmaceuticals has raised a $60 million Series B round and honestly, only one gif comes to mind:
The round was led by Data Collective (DCVC) and participated in by investors both old (Epic Ventures, Lux Capital, Obvious Ventures, Advantage Capital, Felicis, Epic, AME) and new (Mubadala, Menlo Ventures, CRV, Two Sigma, Domo CEO Joshua James, Pluralsight CEO Aaron Skonnard, Qualtrics CEO Ryan Smith, former Ancestry CEO Tim Sullivan).
Chris Gibson, co-founder and CEO of Recursion, released a statement:
“We are identifying potential new therapies in less time and for less money than ever before by eschewing human bias, embracing empiricism, and treating cellular biology as a system too complex and interconnected to be broken down into simple pieces. These funds will enable us to continue our work in drug repurposing, including our partnerships with multiple major pharmaceutical companies, while also building out our own internal pipeline of new drugs and expanding into new therapeutic areas and discovery partnerships. Ultimately, as we continue to grow our massive high-dimensional dataset over hundreds of millions of biological perturbations, we will be well-positioned to make reliable inferences about the trillions of relationships between genes, proteins and chemicals.”
Recursion has gained notoriety for a unique approach to identifying disease treatments, a combination of biology, bioinformatics, and artificial intelligence — as one of their taglines states, “We’re creating a truly tech-first life sciences company.”
Through machine learning, Recursion is able to collect/analyze massive amounts of data and apply that to identifying new drug treatments. This happens on a much quicker and cheaper timeline than traditional outlets, allowing Recursion to scale in a way that freaks people out. In a good way, of course.
As part of the Series B round, DCVC Managing Partner Zachary Bogue will join Recursion’s Board of Directors.